Unapproved stem cell therapies remains a top FDA enforcement priority | Hogan Lovells

Speaking Tuesday at the Food and Drug Law Institute (FDLI) Annual Conference, Mark Raza, FDA Chief Counsel, discussed the investigations priorities for FDA’s Office of the Chief Counsel...

Related Keywords

Florida ,United States ,California ,New Jersey ,Mark Raza ,Wilson Bryan ,Public Health Service Act ,Regenerative Stem Cell Institute ,Drug Law Institute ,Tissue Engineering Branch ,Research Protocol ,Office Of Tissues ,Association For Cell ,Youtube ,Facebook ,Us Department Of Justice ,Smart Surgical Inc ,Biologics Evaluation ,Gene Therapies ,False Claims Act ,Federal Trade Commission ,Untitled Letter ,Good Manufacturing Practice ,Current Good Tissue Practice ,Warning Letter ,Smart Surgical ,Burst Biologics ,Advanced Therapies ,Director Wilson Bryan ,Tissue Engineering ,Annual Conference ,Chief Counsel ,Eleventh Circuit ,Cell Clinic ,Federal Regulations ,Fast Track ,Breakthrough Therapy ,Accelerated Approval ,Regenerative Medicine Advanced Therapy ,